2021 American Academy of Neurology (AAN) Annual Meeting

Stroke occurred at a relatively low rate of 2.2 percent in critically ill COVID-19 patients in the intensive care unit (ICU) — which is lower than previously thought among COVID-19 patients, according to data from the COVID-19 Critical Care Consortium (CCCC) registry presented at the AAN 2021 Meeting.

Use of FT218, an investigational, once-nightly, controlled-release formulation of sodium oxybate (SO), led to clinically significant improvements in sleep parameters in individuals with narcolepsy, according to the secondary endpoint data from the pivotal phase III REST-ON* trial presented at AAN 2021.

Subgroup analyses of the ACHIEVE I and II studies presented at AAN 2021 continued to demonstrate favourable outcomes associated with the 50-mg dose of the FDA-approved oral CGRP* receptor antagonist ubrogepant for acute treatment of migraine in adults, particularly among those who were classified as “triptan-insufficient responders”**. Its safety and tolerability were also consistent across various demographic and clinical characteristic subgroups.

The novel CGRP receptor antagonist zavegepant administered intranasally effectively reduces pain and the most bothersome symptom (MBS) in patients with migraine, shows a study presented at the AAN 2021 Annual Meeting.

Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.

Individuals with depression or anxiety showed earlier onset of Alzheimer's disease (AD) by 2–3 years compared with those without these psychiatric disorders, according to a study presented at the AAN 2021 Meeting — suggesting that patients with symptoms of depression or anxiety should be monitored for cognitive complaints.